Free tool
FAERS Monitor: Erleada
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210951 or its brand name (Erleada, Apalutamide). Reports on generic versions are filed under their own applications.
Reports
12,037
Serious
7,475
62% of reports
Hospitalization
2,717
Death reported
1,541
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash1,336
- fatigue1,240
- death1,203
- hot flush922
- product dose omission issue450
- asthenia443
- diarrhoea421
- dizziness376
- arthralgia371
- off label use365
- fall354
- decreased appetite330
- prostatic specific antigen increased314
- incorrect dose administered295
- pruritus294
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 363 |
| 2019 | 838 |
| 2020 | 1,248 |
| 2021 | 1,023 |
| 2022 | 2,105 |
| 2023 | 1,761 |
| 2024 | 1,837 |
| 2025 | 1,811 |
| 2026 | 1,041 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,122 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prostatic specific antigen increasedSignal | 314 | 40.7 | 36.5 | 11,861 |
| hot flushSignal | 922 | 21.6 | 20.3 | 17,962 |
| rashSignal | 1,336 | 5.4 | 5.1 | 4,831 |
| fatigueSignal | 1,240 | 2.8 | 2.6 | 1,470 |
| product dose omission issueSignal | 450 | 2.7 | 2.4 | 477 |
| decreased appetiteSignal | 330 | 2.5 | 2.2 | 294 |
| deathSignal | 1,203 | 2.4 | 2.3 | 1,065 |
| incorrect dose administeredSignal | 295 | 2.3 | 2.0 | 208 |
| astheniaSignal | 443 | 2.1 | 1.9 | 245 |
| fall | 354 | 1.9 | 1.7 | 142 |
| arthralgia | 371 | 1.6 | 1.4 | 75 |
| pruritus | 294 | 1.3 | 1.2 | 25 |
| dizziness | 376 | 1.3 | 1.2 | 29 |
| diarrhoea | 421 | 1.1 | 1.0 | 7 |
| off label use | 365 | 0.7 | 0.7 | 38 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.